Radiotherapy and hyperthermia for breast cancer patients at high risk of recurrence
Purpose To evaluate the long-term efficacy of combined radiotherapy (RT) and hyperthermia (HT) in a large mono-institutional cohort of breast cancer (BC) patients affected by recurrent, newly diagnosed non-resectable or high risk resected tumor.Materials and methods Records of BC patients treated wi...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-12-01
|
| Series: | International Journal of Hyperthermia |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/02656736.2022.2103593 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849429584723836928 |
|---|---|
| author | Chiara De-Colle Anna Beller Cihan Gani Nicola Weidner Vanessa Heinrich Ulf Lamprecht Stephan Gaupp Otilia Voigt Oliver Dohm Daniel Zips Arndt-Christian Müller |
| author_facet | Chiara De-Colle Anna Beller Cihan Gani Nicola Weidner Vanessa Heinrich Ulf Lamprecht Stephan Gaupp Otilia Voigt Oliver Dohm Daniel Zips Arndt-Christian Müller |
| author_sort | Chiara De-Colle |
| collection | DOAJ |
| description | Purpose To evaluate the long-term efficacy of combined radiotherapy (RT) and hyperthermia (HT) in a large mono-institutional cohort of breast cancer (BC) patients affected by recurrent, newly diagnosed non-resectable or high risk resected tumor.Materials and methods Records of BC patients treated with RT + HT between 1995 and 2018 were retrospectively analyzed. RT doses of 50–70 Gy concurrent to a twice per week superficial HT were applied. For HT, a temperature between 41 and 42 °C was applied for approximately 1 h. Primary endpoint was local control (LC), secondary endpoints comprised toxicity, overall survival (OS), and progression-free survival (PFS).Results A total of 191 patients and 196 RT + HT treatments were analyzed. In 154 cases (78.6%) RT + HT was performed for patients with recurrent BC. Among these, 93 (47.4% of the entire cohort) had received RT prior to RT + HT. Median follow up was 12.7 years. LC at 2, 5, and 10 years was 76.4, 72.8, and 69.5%, respectively. OS at 2, 5, and 10 years was 73.5, 52.3, and 35.5%, respectively. PFS at 2, 5, and 10 years was 55.6, 41, and 33.6%, respectively. Predictive factors for LC were tumor stage, distant metastases, estrogen/progesterone receptor expression, resection status and number of HT fractions. At multivariate analysis tumor stage and receptor expression were significant. No acute or late toxicities higher than grade 3 were observed.Conclusion Combined RT + HT offers long-term high LC rates with acceptable toxicity for patients with recurrent, newly diagnosed non-resectable or resected BC at high risk of relapse. |
| format | Article |
| id | doaj-art-719d7427b2d7407480331bfb58a20b3e |
| institution | Kabale University |
| issn | 0265-6736 1464-5157 |
| language | English |
| publishDate | 2022-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | International Journal of Hyperthermia |
| spelling | doaj-art-719d7427b2d7407480331bfb58a20b3e2025-08-20T03:28:18ZengTaylor & Francis GroupInternational Journal of Hyperthermia0265-67361464-51572022-12-013911010101610.1080/02656736.2022.2103593Radiotherapy and hyperthermia for breast cancer patients at high risk of recurrenceChiara De-Colle0Anna Beller1Cihan Gani2Nicola Weidner3Vanessa Heinrich4Ulf Lamprecht5Stephan Gaupp6Otilia Voigt7Oliver Dohm8Daniel Zips9Arndt-Christian Müller10Department of Radiation Oncology, University Hospital and Medical Faculty Tübingen, Eberhard Karls University Tübingen, Tübingen, GermanyDepartment of Radiation Oncology, University Hospital and Medical Faculty Tübingen, Eberhard Karls University Tübingen, Tübingen, GermanyDepartment of Radiation Oncology, University Hospital and Medical Faculty Tübingen, Eberhard Karls University Tübingen, Tübingen, GermanyDepartment of Radiation Oncology, University Hospital and Medical Faculty Tübingen, Eberhard Karls University Tübingen, Tübingen, GermanyDepartment of Radiation Oncology, University Hospital and Medical Faculty Tübingen, Eberhard Karls University Tübingen, Tübingen, GermanyDepartment of Radiation Oncology, University Hospital and Medical Faculty Tübingen, Eberhard Karls University Tübingen, Tübingen, GermanyDepartment of Radiation Oncology, University Hospital and Medical Faculty Tübingen, Eberhard Karls University Tübingen, Tübingen, GermanyDepartment of Radiation Oncology, University Hospital and Medical Faculty Tübingen, Eberhard Karls University Tübingen, Tübingen, GermanyDepartment of Radiation Oncology, University Hospital and Medical Faculty Tübingen, Eberhard Karls University Tübingen, Tübingen, GermanyDepartment of Radiation Oncology, University Hospital and Medical Faculty Tübingen, Eberhard Karls University Tübingen, Tübingen, GermanyDepartment of Radiation Oncology, University Hospital and Medical Faculty Tübingen, Eberhard Karls University Tübingen, Tübingen, GermanyPurpose To evaluate the long-term efficacy of combined radiotherapy (RT) and hyperthermia (HT) in a large mono-institutional cohort of breast cancer (BC) patients affected by recurrent, newly diagnosed non-resectable or high risk resected tumor.Materials and methods Records of BC patients treated with RT + HT between 1995 and 2018 were retrospectively analyzed. RT doses of 50–70 Gy concurrent to a twice per week superficial HT were applied. For HT, a temperature between 41 and 42 °C was applied for approximately 1 h. Primary endpoint was local control (LC), secondary endpoints comprised toxicity, overall survival (OS), and progression-free survival (PFS).Results A total of 191 patients and 196 RT + HT treatments were analyzed. In 154 cases (78.6%) RT + HT was performed for patients with recurrent BC. Among these, 93 (47.4% of the entire cohort) had received RT prior to RT + HT. Median follow up was 12.7 years. LC at 2, 5, and 10 years was 76.4, 72.8, and 69.5%, respectively. OS at 2, 5, and 10 years was 73.5, 52.3, and 35.5%, respectively. PFS at 2, 5, and 10 years was 55.6, 41, and 33.6%, respectively. Predictive factors for LC were tumor stage, distant metastases, estrogen/progesterone receptor expression, resection status and number of HT fractions. At multivariate analysis tumor stage and receptor expression were significant. No acute or late toxicities higher than grade 3 were observed.Conclusion Combined RT + HT offers long-term high LC rates with acceptable toxicity for patients with recurrent, newly diagnosed non-resectable or resected BC at high risk of relapse.https://www.tandfonline.com/doi/10.1080/02656736.2022.2103593Breast cancerhyperthermiaradiotherapyrecurrent breast cancersuperficial hyperthermia |
| spellingShingle | Chiara De-Colle Anna Beller Cihan Gani Nicola Weidner Vanessa Heinrich Ulf Lamprecht Stephan Gaupp Otilia Voigt Oliver Dohm Daniel Zips Arndt-Christian Müller Radiotherapy and hyperthermia for breast cancer patients at high risk of recurrence International Journal of Hyperthermia Breast cancer hyperthermia radiotherapy recurrent breast cancer superficial hyperthermia |
| title | Radiotherapy and hyperthermia for breast cancer patients at high risk of recurrence |
| title_full | Radiotherapy and hyperthermia for breast cancer patients at high risk of recurrence |
| title_fullStr | Radiotherapy and hyperthermia for breast cancer patients at high risk of recurrence |
| title_full_unstemmed | Radiotherapy and hyperthermia for breast cancer patients at high risk of recurrence |
| title_short | Radiotherapy and hyperthermia for breast cancer patients at high risk of recurrence |
| title_sort | radiotherapy and hyperthermia for breast cancer patients at high risk of recurrence |
| topic | Breast cancer hyperthermia radiotherapy recurrent breast cancer superficial hyperthermia |
| url | https://www.tandfonline.com/doi/10.1080/02656736.2022.2103593 |
| work_keys_str_mv | AT chiaradecolle radiotherapyandhyperthermiaforbreastcancerpatientsathighriskofrecurrence AT annabeller radiotherapyandhyperthermiaforbreastcancerpatientsathighriskofrecurrence AT cihangani radiotherapyandhyperthermiaforbreastcancerpatientsathighriskofrecurrence AT nicolaweidner radiotherapyandhyperthermiaforbreastcancerpatientsathighriskofrecurrence AT vanessaheinrich radiotherapyandhyperthermiaforbreastcancerpatientsathighriskofrecurrence AT ulflamprecht radiotherapyandhyperthermiaforbreastcancerpatientsathighriskofrecurrence AT stephangaupp radiotherapyandhyperthermiaforbreastcancerpatientsathighriskofrecurrence AT otiliavoigt radiotherapyandhyperthermiaforbreastcancerpatientsathighriskofrecurrence AT oliverdohm radiotherapyandhyperthermiaforbreastcancerpatientsathighriskofrecurrence AT danielzips radiotherapyandhyperthermiaforbreastcancerpatientsathighriskofrecurrence AT arndtchristianmuller radiotherapyandhyperthermiaforbreastcancerpatientsathighriskofrecurrence |